[IMMEDIATE RESULTS OF MESOCAVAL SHUNTING IN SURGICAL TREATMENT OF PORTAL HYPERTENSION IN CHILDREN]

Klinichna Khirurhiia
|September 27, 2018
PubMed

Insights

Mesocaval shunting (MCSH) effectively treats pediatric portal hypertension (PH), significantly reducing gastroesophageal varices hemorrhage. This surgical approach offers a higher success rate compared to disconnecting operations.

Area of Science:

  • Pediatric Surgery
  • Hepatology
  • Vascular Surgery

Background:

  • Portal hypertension (PH) in children often leads to severe gastroesophageal varices and hemorrhage.
  • Surgical interventions are crucial for managing PH complications in pediatric patients.
  • Previous surgical methods, like disconnecting operations, have shown limited efficacy.

Purpose of the Study:

  • To analyze the efficacy of mesocaval shunting (MCSH) in treating portal hypertension (PH) in a pediatric cohort.
  • To evaluate MCSH as a treatment option, particularly for recurrent hemorrhage.
  • To compare the outcomes of MCSH with traditional disconnecting operations.

Main Methods:

  • Retrospective analysis of 69 children treated for portal hypertension.
  • Mesocaval shunting (MCSH) was performed, with hemorrhage from gastroesophageal varices as the primary indication.
  • MCSH was utilized as a reoperation in 53.6% of cases.

Main Results:

  • Mesocaval shunting (MCSH) achieved an average decompression of the portal vein system in 30.9% of patients.
  • The overall efficacy of surgical treatment for PH using MCSH reached 85.5%.
  • This represents a significant improvement compared to the 36% efficacy observed after disconnecting operations.

Conclusions:

  • Mesocaval shunting (MCSH) is a highly effective surgical treatment for pediatric portal hypertension (PH).
  • MCSH significantly improves outcomes and reduces hemorrhage in children with PH, especially when compared to disconnecting procedures.
  • The reoperation rate indicates MCSH's utility in complex or previously treated cases.

Related Concept Videos

Shunt Admittances01:26

Shunt Admittances

Shunt admittances play a crucial role in the analysis of transmission lines, particularly for three-phase systems with neutral conductors. When a uniformly charged conductor is positioned above the Earth, it induces an equal but opposite charge on its surface. This interaction creates electric field lines between the conductor and the Earth.
To model this effect, the method of images is employed. This method involves replacing the Earth with an image conductor that mirrors the original...
503
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
610
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
470
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
509
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
623
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.0K